UC Fights Teva's Bid To Invalidate Prostate Cancer Patent
The University of California has denied claims from Teva Pharmaceuticals that a key patent it owns for the blockbuster prostate cancer treatment Xtandi is invalid, firing back with its own allegations...To view the full article, register now.
Already a subscriber? Click here to view full article